Among the 502 submitted specimens, the only tumor carrying coexisting class-1 BRAF mutation and activating NRAS mutations was seen in a pleural effusion specimen taken 3 months after combined therapy with BRAF inhibitor and MEK inhibitor. This evidence concerns the gene MAP2K7 and neoplasm.